Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the publication of a peer-reviewed article in Human Vaccines & Immunotherapeutics (HVI). The article outlines the current cancer vaccine landscape and the challenges facing vaccine technologies for the treatment of solid tumours to explain the advantages of Infinitopes' combined approach to cancer vaccines: incorporating the right targets and the right vectors, for the right patients at the right time.
- The review, entitled "Unlocking Cancer Vaccine Potential: What are the Key Factors?
- ", was an invited contribution from the editorial team at HVI for inclusion in their special edition on cancer vaccines.
- The Company co-authored the review in close collaboration with senior academics from the University of Oxford's cancer vaccine programme.
- Cancer vaccines offer a potential solution to this and, in the past few years alone, we have begun to see some exciting results from different vaccine platforms.